Company logo

FUSN - Fusion Pharmaceuticals Inc.

NASDAQ -> Healthcare -> Biotechnology
Hamilton, Canada

FUSN price evolution
FUSN
(in millions $) 30 Sep 2021 30 Jun 2021 31 Mar 2021 31 Dec 2020
Current assets
Cash $40.27 $29.51 $42.96 $92.41
Short term investments $154.24 $150.9 $186.15 $131.88
Net receivables $0.3 $0.12
Inventory
Total current assets $203.01 $185.16 $233.85 $228.16
Long term investments $45.55 $81.97 $51 $77.08
Property, plant & equipment $9.41 $9.88 $10.06 $1.97
Goodwill & intangible assets
Total noncurrent assets $65.29 $97 $63.45 $82.51
Total investments $199.79 $232.88 $237.15 $208.96
Total assets $268.3 $282.16 $297.31 $310.68
Current liabilities
Accounts payable $3.8 $0.69 $1.02 $3.4
Deferred revenue $4.45 $4.6 $5 $5
Short long term debt $1.33 $1.26 $1.19
Total current liabilities $13.56 $9.37 $7.62 $11.86
Long term debt $5.78 $6.08 $6.32
Total noncurrent liabilities $8.24 $9.24 $10.62 $4.31
Total debt $7.11 $7.34 $7.52
Total liabilities $21.81 $18.61 $18.24 $16.16
Shareholders' equity
Retained earnings -$177.01 -$157.59 -$130.73 -$113.2
Other shareholder equity $0.06 $0.34 $0.28 $0.04
Total shareholder equity $246.5 $263.55 $279.07 $294.51
(in millions $) 31 Dec 2020 31 Dec 2019 30 Jan 2019
Current assets
Cash $92.41 $67.12 $29.05
Short term investments $131.88
Net receivables
Inventory
Total current assets $228.16 $66.55 $30.24
Long term investments $77.08
Property, plant & equipment $1.97 $1.27 $1.1
Goodwill & intangible assets
Total noncurrent assets $82.51 $2.85 $1.16
Total investments $208.96
Total assets $310.68 $69.4 $31.39
Current liabilities
Accounts payable $3.4 $0.83 $0.35
Deferred revenue $5
Short long term debt
Total current liabilities $11.86 $4.27 $1.6
Long term debt
Total noncurrent liabilities $4.31 $6.06 $47.71
Total debt
Total liabilities $16.16 $10.34 $49.31
Shareholders' equity
Retained earnings -$113.2 -$34.77 -$18.59
Other shareholder equity $0.04
Total shareholder equity $294.51 -$33.49
(in millions $) 30 Sep 2021 30 Jun 2021 31 Mar 2021 31 Dec 2020
Revenue
Total revenue $0.33 $0.52
Cost of revenue
Gross Profit $0.33 $0.52
Operating activities
Research & development $12.68 $21.15 $10.72 $4.96
Selling, general & administrative $7.16 $6.64 $6.96 $6.64
Total operating expenses $19.84 $27.79 $17.68 $11.6
Operating income -$19.52 -$27.27 -$17.68 -$11.6
Income from continuing operations
EBIT -$19.49 -$26.94 -$17.44 -$10.72
Income tax expense $0.05 $0.01 -$0.01 $2.58
Interest expense -$0.11 -$0.1 $0.1 $0.08
Net income
Net income -$19.43 -$26.85 -$17.53 -$13.38
Income (for common shares) -$19.43 -$26.85 -$17.53 -$13.38
(in millions $) 31 Dec 2020 31 Dec 2019 30 Jan 2019
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $17.19 $10.63
Selling, general & administrative $20.74 $7.59
Total operating expenses $37.94 $18.22 $10.1
Operating income -$37.94 -$18.22 -$10.1
Income from continuing operations
EBIT -$75.39 -$15.94
Income tax expense $2.61 $0.25 $0.18
Interest expense $0.33
Net income
Net income -$78.33 -$16.19 -$11.65
Income (for common shares) -$79.72 -$16.19
(in millions $) 30 Sep 2021 30 Jun 2021 31 Mar 2021 31 Dec 2020
Net income -$19.43 -$26.85 -$17.53 -$13.38
Operating activities
Depreciation $0.46 $0.43 $0.35 $0.11
Business acquisitions & disposals
Stock-based compensation $2.37 $2.15 $1.72 $1.34
Total cash flows from operations -$21.51 -$17.31 -$20.6 -$3.08
Investing activities
Capital expenditures -$0.16 -$0.21 -$0.58 -$0.06
Investments $32.38 $3.87 -$28.41 -$155.04
Total cash flows from investing $32.22 $3.66 -$29 -$155.1
Financing activities
Dividends paid
Sale and purchase of stock $0.27 $0.21 $0.13 $0.06
Net borrowings
Total cash flows from financing $0.06 $0.21 $0.13 $0.06
Effect of exchange rate -$0.02 $0.02
Change in cash and equivalents $10.76 -$13.46 -$49.45 -$158.13
(in millions $) 31 Dec 2020 31 Dec 2019 30 Jan 2019
Net income -$78.33 -$16.19 -$11.65
Operating activities
Depreciation $0.48 $0.29
Business acquisitions & disposals
Stock-based compensation $3.37 $0.62
Total cash flows from operations -$29.77 -$13.69 -$9.87
Investing activities
Capital expenditures -$1.12 -$0.46
Investments -$209.33
Total cash flows from investing -$210.45 -$0.46 -$1.12
Financing activities
Dividends paid
Sale and purchase of stock $197.68
Net borrowings
Total cash flows from financing $265.51 $52.19 $18.37
Effect of exchange rate
Change in cash and equivalents $25.29 $38.04 $7.38
Fundamentals
Market cap $338.93M
Enterprise value $305.77M
Shares outstanding 43.07M
Revenue $846.00K
EBITDA -$73.23M
EBIT -$74.59M
Net Income -$77.20M
Revenue Q/Q InfinityT%
Revenue Y/Y N/A
P/E ratio -4.39
EV/Sales 361.43
EV/EBITDA -4.18
EV/EBIT -4.10
P/S ratio 400.63
P/B ratio 1.38
Book/Share 5.72
Cash/Share 0.94
EPS -$1.79
ROA -26.66%
ROE -28.50%
Debt/Equity 0.05
Net debt/EBITDA 0.25
Current ratio 14.97
Quick ratio 14.97